MUHC joins Montreal key partners to bring cancer research to the next level
Multi-institutional consortium will provide improved personalized treatments for patients with melanoma and leukemia across Québec
Jun 28, 2018
MONTRÉAL—Leading researchers, cancer centres and hospitals in Montreal, and the Terry Fox Research Institute are partnering to generate new advances in personalized and precision medicine with the aim of improving treatments for 18,000 patients treated annually with cancer.
Researchers and clinicians from the McGill University Health Centre (MUHC) and its Research Institute will join forces with key local players – Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Goodman Cancer Research Centre (GCRC), Centre de Recherche Hôpital Maisonneuve-Rosemont, Institute for Research in Immunology and Cancer (IRIC), Jewish General Hospital (JGH), McGill University, the Université de Montréal, Génome Québec Innovation Centre – to form the multi-institutional Montreal Cancer Consortium (MCC).
For the Terry Fox Research Institute, the launch of this consortium marks another step forward in accelerating precision medicine for all Canadians. This is the second pilot project the Institute has created as part of its strategy for a pan-Canadian network of linked cancer centres.
The Montreal pilot project members will further develop immunotherapy, a new cancer treatment strategy that enhances an individual’s immune system to fight cancer and which has recently shown impressive results for some patients.